Page last updated: 2024-09-05

sb 203580 and geniposide

sb 203580 has been researched along with geniposide in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(geniposide)
Trials
(geniposide)
Recent Studies (post-2010) (geniposide)
3,48941,1374960371

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cao, J; Fang, L; Fu, J; Ge, D; Li, X; Liu, Z; Ran, J; Ran, Y; Shi, Q; Wang, L; Zhang, H; Zhao, H; Zheng, X; Zhou, Y1

Other Studies

1 other study(ies) available for sb 203580 and geniposide

ArticleYear
Geniposide suppresses LPS-induced nitric oxide, PGE2 and inflammatory cytokine by downregulating NF-κB, MAPK and AP-1 signaling pathways in macrophages.
    International immunopharmacology, 2014, Volume: 20, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Butadienes; Cell Line; Cyclooxygenase 2; Dinoprostone; Extracellular Signal-Regulated MAP Kinases; Gardenia; Imidazoles; Inflammation Mediators; Interleukin-6; Iridoids; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred Strains; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Nitriles; Pyridines; Signal Transduction; Sulfones; Transcription Factor AP-1; Tumor Necrosis Factor-alpha

2014